Zenith Capital (Zenith Capital) EPS (Diluted) : $ (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EPS (Diluted)?

Zenith Capital's Earnings per Share (Diluted) for the three months ended in . 20 was $0.00.

Zenith Capital's EPS (Basic) for the three months ended in . 20 was $0.00.

Zenith Capital's EPS without NRI for the three months ended in . 20 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Zenith Capital EPS (Diluted) Historical Data

The historical data trend for Zenith Capital's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EPS (Diluted) Chart

Zenith Capital Annual Data

Trend

EPS (Diluted)

Zenith Capital Quarterly Data

EPS (Diluted)

Competitive Comparison of Zenith Capital's EPS (Diluted)

For the Biotechnology subindustry, Zenith Capital's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zenith Capital's PE Ratio falls into.

Zenith Capital EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Zenith Capital's Diluted EPS for the fiscal year that ended in . 20 is calculated as

Diluted EPS (A: . 20 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(	-	)	/	0
	=

Zenith Capital's Diluted EPS for the quarter that ended in . 20 is calculated as

Diluted EPS (Q: . 20 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(	-	)	/	0
	=

Zenith Capital (OTCPK:ZHCLF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zenith Capital EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines